Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients.

Tytuł:
Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients.
Autorzy:
Sirera G; Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain.; Infectious Diseases Department, Germans Trias i Pujol University Hospital, Badalona, Spain.
Videla S; Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain.; Clinical Research Support Unit (HUB-IDIBELL: Bellvitge University Hospital & Bellvitge Biomedical Research Institute), Clinical Pharmacology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain.; Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, IDIBELL, University of Barcelona, Barcelona, Spain.
Saludes V; Microbiology Department, Laboratori Clinic Metropolitana Nord, Germans Trias i Pujol University Hospital, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
Castellà E; Department of Pathology, Germans Trias i Pujol University Hospital, Badalona, Spain.
Sanz C; Department of Pathology, Germans Trias i Pujol University Hospital, Badalona, Spain.
Ariza A; Department of Pathology, Germans Trias i Pujol University Hospital, Badalona, Spain.
Clotet B; Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain.; IrsiCaixa AIDS Research Institute, University Hospital Germans Trias i Pujol, Badalona, Spain.; Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Martró E; Microbiology Department, Laboratori Clinic Metropolitana Nord, Germans Trias i Pujol University Hospital, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. .; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. .
Źródło:
Scientific reports [Sci Rep] 2022 Aug 01; Vol. 12 (1), pp. 13196. Date of Electronic Publication: 2022 Aug 01.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:
Alphapapillomavirus*/genetics
HIV Infections*/complications
HIV Infections*/epidemiology
Lung Neoplasms*/epidemiology
Lung Neoplasms*/genetics
Oncogene Proteins, Viral*/genetics
Papillomavirus Infections*/complications
Papillomavirus Infections*/epidemiology
Papillomavirus Infections*/metabolism
DNA, Viral ; Humans ; Papillomaviridae/genetics ; Prevalence ; RNA, Messenger/genetics ; Retrospective Studies
References:
Curr Opin Oncol. 2012 Sep;24(5):506-16. (PMID: 22759737)
Clin Microbiol Infect. 2014 Sep;20(9):O585-9. (PMID: 24382308)
J Thorac Oncol. 2013 Jun;8(6):711-8. (PMID: 23571474)
Bull Cancer. 2021 Oct;108(10):908-914. (PMID: 34452700)
Sex Transm Dis. 2012 Nov;39(11):860-7. (PMID: 23064535)
Lancet Oncol. 2009 Apr;10(4):321-2. (PMID: 19350698)
Infect Agent Cancer. 2010 Jan 22;5:2. (PMID: 20180999)
PLoS One. 2016 Mar 01;11(3):e0149679. (PMID: 26930653)
JAMA. 2012 Feb 15;307(7):693-703. (PMID: 22282321)
PLoS One. 2017 Feb 15;12(2):e0172240. (PMID: 28199413)
J Clin Pathol. 1990 Jan;43(1):52-6. (PMID: 2155946)
J Cancer Res Clin Oncol. 2019 Aug;145(8):1919-1937. (PMID: 31236668)
Case Rep Pathol. 2014;2014:608521. (PMID: 24660084)
Cancer Lett. 2011 Dec 8;311(2):160-70. (PMID: 21868151)
Nat Rev Cancer. 2007 Oct;7(10):778-90. (PMID: 17882278)
Anticancer Res. 2012 Aug;32(8):3085-9. (PMID: 22843877)
Med Clin (Barc). 2018 Apr 23;150(8):291-296. (PMID: 28528797)
J Natl Cancer Inst. 2011 May 4;103(9):753-62. (PMID: 21483021)
Clin Infect Dis. 2007 Jul 1;45(1):103-10. (PMID: 17554710)
J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22. (PMID: 19770804)
Ann Intern Med. 2000 Mar 7;132(5):369-72. (PMID: 10691587)
AIDS. 2012 May 15;26(8):1017-25. (PMID: 22382152)
Carcinogenesis. 2009 Oct;30(10):1722-8. (PMID: 19620233)
J Natl Cancer Inst. 2011 Jul 20;103(14):1112-22. (PMID: 21685357)
J Acquir Immune Defic Syndr. 2010 Nov;55(3):375-9. (PMID: 20736841)
Cancer Res. 2007 Nov 15;67(22):10686-93. (PMID: 18006810)
Clin Infect Dis. 2012 Nov;55(9):1228-35. (PMID: 22776851)
Transl Lung Cancer Res. 2015 Dec;4(6):678-88. (PMID: 26798577)
Br J Cancer. 2012 Jan 31;106(3):447-52. (PMID: 22240797)
Lancet. 2013 Sep 7;382(9895):877-87. (PMID: 23827089)
AIDS Rev. 2016 Jul-Sep;18(3):138-144. (PMID: 27438573)
J Mol Biol. 1994 Nov 4;243(4):568-73. (PMID: 7525969)
DNA Cell Biol. 2004 Apr;23(4):249-60. (PMID: 15142382)
Oncol Rep. 2006 Jul;16(1):183-9. (PMID: 16786144)
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:14-26. (PMID: 29037457)
AIDS. 2015 Jun 19;29(10):1183-93. (PMID: 25888645)
J Clin Oncol. 2006 Mar 20;24(9):1383-8. (PMID: 16549832)
J Mol Diagn. 2015 May;17(3):293-301. (PMID: 25791291)
Int J Gynecol Pathol. 2009 Sep;28(5):497-501. (PMID: 19696623)
Int J Cancer. 2017 Mar 1;140(5):1186-1198. (PMID: 27859245)
Papillomavirus Res. 2017 Jun;3:7-10. (PMID: 28720459)
Curr Opin HIV AIDS. 2014 Jan;9(1):34-40. (PMID: 24225382)
AIDS. 2007 Jan 11;21(2):207-13. (PMID: 17197812)
HIV Med. 2013 Feb;14(2):77-84. (PMID: 22934689)
Br J Cancer. 2007 Jul 2;97(1):85-91. (PMID: 17579626)
Arch Pathol Lab Med. 2020 May;144(5):620-625. (PMID: 31509455)
J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62. (PMID: 9049358)
Cancer Rep (Hoboken). 2021 Aug;4(4):e1350. (PMID: 33624444)
Br J Cancer. 1995 Feb;71(2):344-9. (PMID: 7841051)
J Natl Cancer Inst. 2005 Mar 16;97(6):425-32. (PMID: 15770006)
Vaccine. 2021 Apr 22;39(17):2344-2350. (PMID: 33812740)
Substance Nomenclature:
0 (DNA, Viral)
0 (Oncogene Proteins, Viral)
0 (RNA, Messenger)
Entry Date(s):
Date Created: 20220801 Date Completed: 20220803 Latest Revision: 20221013
Update Code:
20240105
PubMed Central ID:
PMC9343353
DOI:
10.1038/s41598-022-17237-5
PMID:
35915124
Czasopismo naukowe
HIV-infected individuals could be at a greater risk for developing lung cancer than the general population due to the higher prevalence in the former of human papillomavirus (HPV) in the oral cavity and higher smoking rates. Our aim was to assess HPV prevalence and E6 viral oncogene transcription in lung cancer samples from HIV-infected individuals. This was a single-center, retrospective study of a cohort of HIV-1-infected patients diagnosed with and treated for lung cancer. Pathological lung samples archived as smears or formalin-fixed paraffin-embedded blocks were subjected to HPV genotyping, detection of human p16 protein and assessment for HPV E6 mRNA expression. Lung cancer samples from 41 patients were studied, including squamous cell carcinoma (32%), adenocarcinoma (34%), non-small cell cancer (27%), and small cell cancer (7%). HPV DNA was detected in 23 out of 41 (56%, 95% CI 41-70%) of samples and high-risk (HR)-HPV types were detected in 16 out of 41 (39%, 95% CI 26-54%), HPV-16 being the most prevalent [13/16 (81.3%, 95% CI 57.0-93%]. In samples with sufficient material left: expression of p16 was detected in 3 out of 10 (30%) of HR-HPV DNA-positive tumors and in 3 out of 7 (43%) of the negative ones; and E6 mRNA was detected in 2 out of 10 (20%) of HPV-16-positive samples (squamous lung cancers). These two patients had a background of a previous HPV-related neoplasia and smoking. HR-HPV DNA detection was prevalent in lung cancers in HIV-infected patients. However, viral oncogene expression was limited to patients with previous HPV-related cancers.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies